Introduction
============

Due to advances in endoscopic therapeutic techniques such as mucosal resection, gastric cancers have usually been treated at an early stage. If it is completely resected by histology, gastric cancer does not recur at the treated scar. Different from surgery, almost all gastric mucosa remains with malignant potential. Multiple gastric cancers are observed in approximately 3.7--5.7% of all patients with gastric cancer \[[@B1], [@B2]\]. Uemura *et al.* \[[@B3]\] reported that the rates of metachronous multiple gastric cancer were 9% during three years after the resection of the first gastric cancer. Endoscopists should carefully follow the patients treated with endoscopic resection for gastric cancers in order to find metachronous multiple gastric cancers. It is clinically and economically important to narrow the number of patients followed by the high risk factors. However, it is not well-known what these risk factors are or the predictive factors for the development of metachronous multiple gastric cancers.

Microsatellite instability (MSI) due to defects in mismatch repair genes such as *hMLH1* and *hMSH2* is now widely recognized as an important mechanism in tumorigenesis \[[@B4]--[@B6]\]. In addition, epigenetic silencing of tumor suppressor or tumor-related genes and mismatch repair genes, due to hypermethylation of cytosine guanine dinucleotides (CpG) sites in the 5' promoter resions, has emerged recently as one of the pivotal genetic alterations in cancer development \[[@B7], [@B8]\]. Several reports have been published about methylation of various genes, including *hMLH1*, O^6^*-methylguanine DNA methylyransferase (MGMT)*, *E-cadherin* and *p16*, in chronic gastritis, intestinal metaplasia and adenomas to carcinomas of the stomach \[[@B9]--[@B13]\]. However, few reports have described about the correlation between the presence of MSI and DNA hypermethylation in multiple gastric cancers \[[@B14]--[@B16]\]. In order to find genetic and epigenetic markers to identify high risk patients for multiple early gastric cancers after treatment with endoscopic mucosal resection (EMR), we analyzed the MSI status and hypermethylation of multiple tumor-related genes in these patients comparing single gastric cancer with synchronous and metachronous multiple gastric cancers.

Materials and Methods
=====================

Patients
--------

Sixty-four adenocarcinomas, including 32 solitary tumors from 32 patients and 32 multiple tumors from 14 patients treated with endoscopic mucosal resection at the Osaka City University Hospital between 1993 and 2002 were studied. Written informed concent was obtained from all patients. These patients received follow-up esophago-gastro-duodenoscopy at 1 month, 3 months and then every 6 months after the first cancer treatment. The mean age of the patients with a single gastric cancer and with synchronous and metachronous multiple gastric cancers was 67.1 and 71.5 years, respectively. The male to female ratios of these groups were 21/11 and 12/2, respectively. Active *Helicobacter pylori* (*H. pylori)* infection was identified by histology, serology test for *H. pylori* antibody and urea breath test. Active *H. pylori* infection was detected in 14 patients (43.8%) and in 8 patients (57.1%), respectively.

DNA extraction
--------------

Tissue sections, 4 µm in thickness, were cut from formalin-fixed and paraffin-embedded blocks were placed on a glass slide and stained with hematoxylin and eosin. These tissue sections were then dehydrated in graded ethanol solutions and dried. Cancerous and normal tissues on the slide were carefully dissected using tooth picks, separately, using the serial haematoxylin-eosin stained sections under the microscope as a reference. DNA was extracted from the tissues with 50 µl of extraction buffer (100 mM Tris-HCl, pH 7.8, 2 mM EDTA, 400 µg/ml of proteinase K) at 55°C overnight. The tubes were boiled for 7 min to inactivate the proteinase K, and then 1 µl of these extracts were used for each polymerase chain reaction (PCR) amplification.

Microsatellite assay
--------------------

Six microsatellite markers (BAT-25, BAT-26, D5S346, D17S250, D1S191 and BAT40) were analyzed. The forward primers were fluorescein labeled with \[6-FAM\] (D1S191, D17S250, BAT-26 and BAT-40), \[VIC\] (D5S346) and \[TAMRA\] (BAT-25). PCR was performed in total 15 µl reaction volumes containing 1 µl template DNA, 0.56 µmol/l of each primer, 74.7 µmol/l of dATP, dGTP, dCTP and dTTP, respectively, 4.5 mmol/l of MgCl~2~ and 0.075 U of Ampli*Taq*Gold (Applied Biosystems, Foster City, CA). The PCR amplification consisted of 45 cycles (94°C for 45 s, 55°C for 45 s and 72°C for 45 s) after the initial *Taq* DNA polymerase activation step (95°C for 10 min), followed by a final extension for 10 min at 72°C. PCR products were electrophoresed in ABI PRISM 310 Genetic Analyzer along with GeneScan-500 \[ROX\] molecular weight standard (Applied Biosystems). The size of the PCR product was analyzed using GeneScan software (Applied Biosystems). Tumors were characterized as MSI (+) (= MSI-high) if two or more of the markers showed instability. When one or none of the markers showed instability, tumors were designated as MSI (−) (= MSS/MSI-low). We considered MSS (microsatellite stable) and MSI-low cases together as MSI (−) because there was no statistical difference between them \[[@B17]\].

Immunohistochemistry
--------------------

Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections using a streptavidin-biotin system (Dakocytomation, Copenhagen, Denmark). Mouse monoclonal antibody to hMLH1 (diluted 1:100), (Pharmingen, San Diego, CA) was used after antigen retrieval by microwave. Slides were counterstained with Meyer's haematoxylin. The evaluation of hMLH1 immunoreativity was categorized as positive or negative. Cases with definite nuclear staining in more than 30% of the tumor cells were categorized as positive and those with definite nuclear staining less than 30% of the tumor cells as negative.

Bisulfite modification and methylation-specific PCR (MSP)
---------------------------------------------------------

The methylation status of the CpG island in the promoter region of *hMLH1*, *MGMT*, *p16* and *E-cadherin* was determined by bisulfite treatment of DNA followed by methylation-specific PCR with some modifications \[[@B18]\]. In brief, 2 µg of microdissected genomic DNA was denatured by treatment with NaOH and modified with 3 M sodium bisulfite for 16 h. DNA samples were purified with Wizard DNA purification resin (Promega, Madison, WI), treated with NaOH, precipitated with ethanol, and resuspended in 20 µl of distilled water. The primer sequences of each gene and conditions of the PCRs were in accordance with those of the previous reports \[[@B18]--[@B20]\]. Ten µl of PCR products underwent electrophoresis on 8% non-denaturing polyacrylamide gels, then visualized under UV illumination using an ethidium bromide stain. DNA from Colo320 colon cancer cell line treated with CpG methyltransferase (New England Biolabs, Beverly, MA) was used as a positive control for methylation and distilled water was used as a negative control.

Statistical analysis
--------------------

Data were analyzed using the SPSS software (SPSS Inc., Chicago, IL). Fisher's exact test were used for analysis of most of the categorical or numerical data, respectively. In addition, the cumulative rate of secondary gastric cancer development in patients with MSI (+) gastric cancer and that in patients with MSI (−) gastric cancer were calculated by the Kaplan-Meier method. A *p* value less than 0.05 was regarded as statistically significant.

Results
=======

The frequency of MSI
--------------------

Representative results of microsatellite analyses are shown in Fig. [1](#F1){ref-type="fig"}. MSI (+) was detected in 5 of the 14 (35.7%) patients with multiple gastric cancers (MGCs). On the other hand, MSI (+) was only detected in 3 of the 32 (9.3%) patients with solitary gastric cancers (SGC) (Table [1](#T1){ref-type="table"}). The frequency of MSI (+) was significantly higher in the patients with multiple gastric cancers than that in those with a single gastric cancer (*p*\<0.001).

There was no statistical difference between SGC and MGC in evaluated clinicopathologic features including age, sex, tumor histology, tumor location or *H. pylori* infection (Table [2](#T2){ref-type="table"}).

Promoter hypermethylation of hMLH1, MGMT, p16 and E-cadherin
------------------------------------------------------------

Representative results of MSP of *hMLH1*, *MGMT*, *p16*and *E-cadherin* are shown in Fig. [2](#F2){ref-type="fig"}. Table [3](#T3){ref-type="table"} summarizes the frequency of the promoter hypermethylation of each gene in early SGCs and MGCs. Hypermethylation of *hMLH1* was more frequently observed in MGCs than in SGCs (*p*\<0.01), whereas significant difference was not observed in the frequency of *MGMT*, *p16* and *E-cadherin* promoter methylation between the 2 groups.

Relationship between promoter hypermethylation and MSI
------------------------------------------------------

Next, we compared the frequency of *hMLH1*, *MGMT*, *p16* and *E-cadherin* promoter methylation and microsatellite status in the early gastric cancers (Fig. [3](#F3){ref-type="fig"}). Methylation of *hMLH1* was present in 70% (7/10) of MSI (+) tumors and in 14.8% (8/54) of MSI (−) tumors (*p*\<0.01). Methylation of *MGMT* was detected in 70% (7/10) of MSI (+) tumors and in 33.3% (18/54) of MSI (−) tumors (*p*\<0.01). Methylation of *E-cadherin* was present in 30% (3/10) of MSI (+) tumors and in 18.5% (10/54) of MSI (−) tumors (*p* = 0.058). Methylation of *p16* was present in 50% (5/10) of MSI (+) tumors and in 18.5% (10/54) of MSI (−) tumors (*p*\<0.01).

Relationship between promoter hypermethylation and expression of hMLH1
----------------------------------------------------------------------

Finally, we analyzed the relationship between promoter hypermethylation of *hMLH1* and its expression (Table [4](#T4){ref-type="table"}). Of 15 gastric cancers with promoter methylation of *hMLH1* gene, 10 (66.7%) showed absent or decreased hMLH1 expression. In contrast, 40 of 49 gastric cancers (81.6%) without *hMLH1* gene methylation showed intense nuclear immunoreactivity of hMLH1. Absent or decreased hMLH1 expression was significantly correlated with promoter hypermethylation of the gene (*p*\<0.001). In addition, *hMLH1* promoter hypermethylation was detected in 70% (7/10) of MSI (+) tumors and was associated with absent or decreased hMLH1 expression in all 7 cases. In contrast, 8 of 54 (14.8%) MSI (−) tumors demonstrated *hMLH1* promoter hypermethylation. Five of these cases showed normal nuclear immunoreactivity of hMLH1.

Discussion
==========

This is the first report to evaluate the MSI status and hypermethylation of several tumor-related genes in MGCs of patients treated with EMR. We demonstrated that the frequency of MSI (+) was significantly higher in the patients with MGCs than those with SGCs and that hypermethylation of *hMLH1* was more frequently detected in MGCs than in SGCs (*p*\<0.01). Therefore, MSI (+) and hypermethylation of *hMLH1* may serve as a useful marker for identifying individuals who may be at risk of developing MGCs.

By the development of the endoscopic therapeutic techniques, endoscopic resection can cure most of the early gastric cancers. However, because the background gastric mucosa in such cases are accompanied by chronic gastritis and intestinal metaplasia, development of metachronous multiple gastric cancers in other sites is a major problem. Uemura *et al.* \[[@B3]\] reported that no new gastric cancer cases were detected for 2 years in patients treated with *H. pylori* eradication after the resection of the first cancer and on the other hand, 9% of the patients with *H. pylori* had metachronous early gastric cancer in other site. Park *et al.* \[[@B21]\] reported that the expression of DNA mismatch repair proteins increased in the gastric mucosa after *H. pylori* eradication. Chan *et al.* \[[@B22]\] showed disappearing of *E-cadherin* promoter hypermethylation status after *H. pylori* eradication in patients with chronic gastritis. If *H. pylori* eradication therapy may reverse methylation of tumor suppressor or tumor-related genes, early reversal of promoter methylation at the residual gastric mucosa in the patients treated with EMR may prevent the development of metachronous gastric cancer. This indicates the possibility of useful targeting therapy. It is very valuable to find tumor suppressor or tumor-related genes that have been methylated in the MGCs of the patients treated with EMR.

Based on previous reports \[[@B9]--[@B13]\], we selected four genes (*hMLH1*, *MGMT*, *E-cadherin*, *p16*) and examined the methylation status of these genes in the present study. Hypermethylation of *hMLH1* was more frequently detected in MGCs than in SGCs (*p*\<0.01), whereas significant difference was not observed in the frequency of *MGMT*, *p16* or *E-cadherin* promoter methylation between the 2 groups. Regarding *hMLH1*, it is known that hypermethylation of its promoter region leads to diminished protein expression and is significantly associated with genome-wide instability of simple repeat sequences, referred to as MSI (+) \[[@B9], [@B12], [@B15], [@B20]\]. In the present study, absent or decreased hMLH1 expression was significantly correlated with promoter hypermethylation of the gene by immunohistochemistry. In addition, *hMLH1* promoter hypermethylation was detected in 70% of MSI (+) tumors and was associated with absent or decreased hMLH1 expression in all these cases. In contrast, 14.8% of MSI (−) tumors demonstrated *hMLH1* promoter hypermethylation. Inactivation of hMLH1 through promoter hypermethylation may cause MGCs following the MSI pathway.

There were some reports about MSI or hypermethylation of tumor-related genes in multiple gastric cancers \[[@B14]--[@B16]\]. Miyoshi *et al.* \[[@B14]\] showed that the frequency of MSI was significantly higher in the patients with multiple gastric cancers, both synchronous and metachronous, than in those with a single gastric cancer. Kawamura *et al.* \[[@B16]\] have reported that thirty percent of patients with metachronous recurrence of gastric cancer after undergoing successful endoscopic resection showed MSI, whereas none of the patients with nonrecurrent disease did so. However, in these two reports, they did not examine the methylation status of tumor-related genes in multiple gastric cancers. Sakata *et al.* found that hypermethylation of the *hMLH1* promoter was detected in all of SGCs and MGCs with MSI \[[@B15]\]. They focused on aberrant methylation in a single gene and their samples were obtained at the time of surgery including only synchronous multiple gastric cancers. No reports have found the correlation between the presence of MSI and various kinds of hypermethylation of tumor-related genes in metachronous multiple gastric cancers.

We also investigated the relationship between the hypermethylation of the promoters of four genes (*hMLH1*, *MGMT*, *E-cadherin*, *p16*) and MSI. Significant association was detected between promoter hypermethylation of these three genes except *E-cadherin* and MSI (+) cancers (*p*\<0.01). Some previous reports found that significant associations were found between *hMLH1* promoter hypermethylation and MSI (+) cancers in different organs \[[@B23]--[@B25]\]. In gastric cancer, Toyota *et al.* \[[@B9]\] showed that cases showing methylation at more than three of the five loci (methylated in tumors (MINT) 1, 2, 12, 25 and 31) were designated as CpG island methylator phenotype (CIMP) positive, and such CIMP (+) gastric cancers accompanied with the methylation of known genes, including *p16* and *hMLH1*. According to these findings, CpG island methylation may precede the development of MSI and methylation of some genes may occur in absence of MSI in many tumors. The results of the present study indicates that methylation of *hMLH1*, *MGMT*, and *p16* may be involved in the development of MSI, and also play a crucial role in early gastric carcinogenesis. The overall frequency of *E-cadherin* promoter hypermethylation in early gastric carcinomas in the present study was 20.3% (13/64), which was lower than those previously reported \[[@B18], [@B26], [@B27]\]. Tamura *et al.* \[[@B28]\] showed that *E-cadherin* promoter hypermethylation occurred more frequently in carcinomas of the undifferentiated scattered type than in other histological subtypes. The tumors analyzed in this study were histologically differentiated adenocarcinomas comprising early cancers (depth of invasion limited to the mucosa or submucosa). This may affect the frequency of *E-cadherin* promoter methylation in this study. If further examination of large sample size is done, methylation of *MGMT* and *p16*, not *E-cadherin* in early gastric cancer may be a useful molecular marker for the prediction of MGC development.

In conclusion, *hMLH1* may be one of the frequent methylation targets in MGCs and its inactivation through promoter hypermethylation may cause MGCs following the MSI pathway. MSI (+) and *hMLH1* methylation in gastric cancer may be a useful molecular marker for the prediction of MGC development and these patients will need to be closely observed by endoscopy as high risk patients even if the treatment with EMR were successful. We also put our hopes in developing some gene-targeting therapies that may reverse methylation at the residual gastric mucosa in the patients treated with EMR in order to prevent the development of metachronous gastric cancer.

![Representative results of microsatellite analyses in early gastric carcinomas. In case 2 (upper panel), each microsatellite demonstrates identical pattern between normal gastric mucosa (N) and cancer (T). On the other hand, BAT-26, BAT-25 and BAT 40 show extra-peaks (arrows) in cancer DNA from case 16.](jcbn2007026f01){#F1}

![Representative results of methylation-specific PCR of *hMLH1*, *p16*, *MGMT* and *E-cadherin* by using both methylated (M) and unmethylated (U) specific primers in gastric cancer. Methylated PCR products were detected in case 57 for *hMLH1*, in case 17 and 18 for *p16*, in case 47, 49 and 50 for *MGMT* and in case 31 for *E-cadherin*. P, positive control.](jcbn2007026f02){#F2}

![Comparison of the frequency of the promoter hypermethylation of *hMLH1*, *MGMT*, *p16* and *E-cadherin* in MSI (+) and MSI (−) gastric cancers. The incidences of promoter hypermethylation of *hMLH1*, *MGMT* and *p16* are significantly higher in the MSI (+) tumors than in the MSI (−) tumors. On the other hand, significant difference is not observed in the frequency of *E-cadherin* promoter methylation between the 2 groups.](jcbn2007026f03){#F3}

###### 

Comparison of the frequency of microsatellite instability in early multiple gastric cancers and early solitary gastric cancers

                                           total   MSI (+)[a](#tblfn1){ref-type="table-fn"} (%)   MSI (−)[b](#tblfn2){ref-type="table-fn"} (%)   *p* value
  ---------------------------------------- ------- ---------------------------------------------- ---------------------------------------------- -----------
  Patients with solitary gastric cancers   32      3 (9.3%)                                       29 (90.7%)                                     \<0.001
  Patients with multiple gastric cancers   14      5 (35.7%)                                      9 (64.3%)                                      
  Solitary gastric lesions                 32      3 (9.3%)                                       29 (90.7%)                                     0.02
  Multiple gastric lesions                 32      7 (21.9%)                                      25 (78.1%)                                     

MSI (+); two or more of the markers showed instability

MSI (−); one or none of the markers showed instability

###### 

Comparison of clinicopathological factors between early multiple gastric cancers and early solitary gastric cancers

                        Solitary gastric cancer (*n* = 32 cases)   Multiple gastric cacner (*n* = 14cases, 32 lesions)   *p* value
  --------------------- ------------------------------------------ ----------------------------------------------------- -----------
  Age                   67.1                                       71.5                                                  N.S
  Sex                                                                                                                    
   male                 21                                         12                                                    N.S
   female               11                                         2                                                     
  Location                                                                                                               
   U                    3                                          6                                                     N.S
   M                    8                                          6                                                     
   L                    21                                         20                                                    
  Histologic type                                                                                                        
   Well                 29                                         31                                                    N.S
   Moderate             3                                          1                                                     
  Depth of invasion                                                                                                      
   m                    29                                         30                                                    N.S
   sm                   3                                          2                                                     
  Helicobacter pylori                                                                                                    
   Positive             14                                         8                                                     N.S

N.S.; not significant

###### 

Methylation frequencies and number of methylated genes in early multiple gastric cancers and early solitary gastric cancers

                                                               Solitary gastric cancers *n* = 32 (%)   Multiple gastric cacners *n* = 32 (%)   *p* value
  ----------------------------------------- ------------------ --------------------------------------- --------------------------------------- -----------
  *hMLH1*                                   Unmethylated (%)   27 (84.4)                               22 (68.7)                               \<0.01
                                            Methylated (%)     5 (15.6)                                10 (31.3)                               
  *MGMT*[a](#tblfn3){ref-type="table-fn"}   Unmethylated (%)   19 (59.4)                               20 (62.5)                               0.653
                                            Methylated (%)     13 (40.6)                               12 (37.5)                               
  *p16*                                     Unmethylated (%)   25 (78.1)                               24 (75.0)                               0.605
                                            Methylated (%)     7 (21.9)                                8 (25.0)                                
  *E-cadherin*                              Unmethylated (%)   25 (78.1)                               26 (81.2)                               0.586
                                            Methylated (%)     7 (21.9)                                6 (18.8)                                

*MGMT*, O^6^*-methylguanine DNA methylyransferase*

###### 

Correlation with promoter methylation status and protein expression of *hMLH1* in gastric cancers

  *hMLH1* gene promoter status   Total   hMLH1 immunoreactivity   
  ------------------------------ ------- ------------------------ --------------
  Methylated                     15      5 (33.3)                 10 (66.7)^a^
  Unmethylated                   49      40 (81.6)                9 (18.4)^a^

^a^ Significant difference (*p*\<0.001) by Fisher's exact test
